Long-term efficacy of dupilumab in severe asthma by baseline oral corticosteroid dose

BACKGROUND: Dupilumab has been shown to improve clinical outcomes long term while reducing oral corticosteroid (OCS) dose in patients with severe OCS-dependent asthma. This post hoc analysis assesses the impact of OCS dose at baseline (

• Domingo, C.
• Rabe, K. F.
• Price, D.
• Brusselle, G.
• Wechsler, M. E.
• Xia, C.
• Pandit-Abid, N.
• Gall, R.
• Rowe, P. J.
• Deniz, Y.
• Jacob-Nara, J. A.
• Radwan, A.